Axsome Therapeutics Sees Significant Stock Surge Following Patent Settlement

In an exciting turn of events, Axsome Therapeutics (NASDAQ:AXSM) has experienced a remarkable premarket price surge of 15.4%, bringing its stock price to $122.00. This increase is attributed to the recent announcement of a settlement agreement with Teva Pharmaceuticals regarding patent litigation related to its product, AUVELITY.

The settlement resolves all ongoing patent disputes between Axsome and Teva, which arose when Teva submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of AUVELITY. Under the terms of the agreement, Teva will be granted a license to sell its generic version of AUVELITY starting on or after March 31, 2039, or September 30, 2038, depending on the status of pediatric exclusivity.

Herriot Tabuteau, MD, the CEO of Axsome Therapeutics, expressed pride in the company’s commitment to innovation in treating central nervous system disorders. He stated, "The resolution of this patent litigation underscores the value of that innovation as it relates to AUVELITY, and more broadly reflects the strength of Axsome's intellectual property portfolio." This positive sentiment has likely contributed to the surge in stock price as investors respond favorably to the news.

As of the latest data, the trading volume for Axsome's stock in premarket trading has reached 79,635 shares, indicating strong investor interest. The resolution of this litigation not only enhances Axsome's market position but also reassures investors about the company's future prospects in the competitive biopharmaceutical landscape.

With a strong pipeline of treatments for central nervous system conditions, Axsome Therapeutics is poised for continued growth and innovation. Investors will be watching closely as the company navigates its next steps following this significant legal victory.